Eli Lilly's (LLY +0.9%) Phase III Pointbreak trial did not meet its primary endpoint of improved...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly's (LLY +0.9%) Phase III Pointbreak trial did not meet its primary endpoint of improved overall survival in lung-cancer patients, although it did meet a secondary goal of improved progression-free survival for the Alimta arm. (PR)